Finance

Lists
Why is ABT up 3.73%?
Dive Deeper
ABT:NYSE
Abbott Laboratories
$110.16
+3.73%
(+3.96) 1D
$110.44
+0.25% (+0.28)
After hours
Closed: Nov 2, 4:02:48 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABT...
Open
$106.89
High
$110.48
Low
$106.40
Mkt. cap
190.62B
Avg. vol.
9.30M
Volume
8.85M
Dividend
2.29%
Quarterly dividend
$0.63
Ex-dividend date
Oct 15, 2026
P/E ratio
40.86
52-wk high
$132.02
52-wk low
$81.97
EPS
$2.70
Beta
0.59
Shares outstanding
1.73B
No. of employees
115K
Open
$106.89
High
$110.48
Low
$106.40
Mkt. cap
190.62B
Avg. vol.
9.30M
Volume
8.85M
Dividend
2.29%
Quarterly dividend
$0.63
Ex-dividend date
Oct 15, 2026
P/E ratio
40.86
52-wk high
$132.02
52-wk low
$81.97
EPS
$2.70
Beta
0.59
Shares outstanding
1.73B
No. of employees
115K
News stories
From web sources and news partners
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories
CEORobert B. Ford
Employees115K
Founded1888
HeadquartersChicago, Illinois, United States
SectorMedical device
Websiteabbott.com
Analyst ratings
Based on 19 analysts giving stock ratings to ABT in the past 3 months
Strong buy
Buy
17
Hold
2
Sell
0
12-month forecast
Based on 19 Wall Street analysts offering 12 month price targets for ABT in the last 3 months.
Highest
Current $110.16
$135.00 (+22.55%)
Average
$121.94 (+10.69%)
Lowest
$115.00 (+4.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Adam Maeder
Piper Sandler
Buy
Maintained
$118.00
+7.1%
11/02/2026
Travis Steed
Bank of America Securities
Buy
Reiterated
$115.00
+4.4%
10/30/2026
David Toung
Argus Research
Hold
Downgraded
-
-
10/26/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$120.00
+8.9%
10/23/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$120.00
+8.9%
10/22/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$115.00
+4.4%
10/22/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$118.00
+7.1%
10/22/2026
Kendall Au
RBC Capital
Buy
Reiterated
$125.00
+13.5%
10/21/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$125.00
+13.5%
10/21/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
$118.00
+7.1%
10/22/2026
David Rescott
Robert W. Baird
Buy
Maintained
$123.00
+11.7%
10/22/2026
Marie Thibault
BTIG
Buy
Maintained
$125.00
+13.5%
10/21/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
$120.00
+8.9%
10/23/2026
Christopher Pasquale
Barclays
Buy
Maintained
$120.00
+8.9%
10/22/2026
Joanne Wuensch
Citi
Buy
Reiterated
$122.00
+10.7%
10/22/2026
Unknown Analyst
Leerink Partners
Hold
Maintained
-
-
10/12/2026
Matt Miksic
Barclays
Buy
Maintained
$120.00
+8.9%
10/07/2026
Himanshu Patel
J.P. Morgan
Buy
Initiated
$120.00
+8.9%
10/07/2026
Ed Ridley-Day
Rothschild & Co Redburn
Buy
Upgraded
$127.00
+15.3%
10/02/2026
Matthew Taylor
Jefferies
Buy
Reiterated
$135.00
+22.5%
08/21/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
$130.00
+18%
08/13/2026
Danielle Antalffy
UBS
Buy
Reiterated
$125.00
+13.5%
07/28/2026
Patrick Wood
UBS
Buy
Reiterated
$125.00
+13.5%
07/28/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$135.00
+22.5%
07/17/2026
Jayson Bedford
Raymond James
Buy
Maintained
-
-
07/17/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$110.00
-0.1%
06/29/2026
David Roman
Goldman Sachs
Buy
Maintained
$113.00
+2.6%
05/31/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
$92.00
-16.5%
04/21/2026
Anthony Petrone
Mizuho Securities
Hold
Maintained
$115.00
+4.4%
04/20/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
$115.00
+4.4%
04/17/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$120.00
+8.9%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$121.00
+9.8%
04/09/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
04/01/2026
Last report
Oct 21, 2026
Fiscal period
Q3 2026
$1.42 / $1.42
+0.03%beat
Revenue / Est. (USD)
13.01B / 12.99B
+0.18%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
11.46B
11.16B
12.59B
13.01B
Cost of goods sold
4.91B
4.89B
5.32B
5.59B
Cost of revenue
4.91B
4.89B
5.32B
5.59B
Research and development expenses
720.00M
767.00M
892.00M
908.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.93B
3.58B
3.87B
4.20B
Operating expense
4.07B
4.77B
5.42B
5.95B
Total operating expenses
8.98B
9.66B
10.74B
11.54B
Operating income
2.48B
1.50B
1.85B
1.48B
Other non operating income
-15.00M
-
-25.00M
173.00M
EBT including unusual items
2.36B
1.45B
1.52B
1.23B
EBT excluding unusual items
2.44B
1.45B
1.52B
1.36B
Income tax expense
582.00M
372.00M
596.00M
311.00M
Effective tax rate
24.68%
25.67%
39.11%
25.26%
Other operating expenses
-
-
-
-
Net income
1.78B
1.08B
928.00M
920.00M
Net profit margin
15.50%
9.65%
7.37%
7.07%
Earnings per share
1.50
1.15
1.31
1.42
Interest and investment income
78.00M
106.00M
52.00M
-
Interest expense
-120.00M
-174.00M
-351.00M
-297.00M
Net interest expenses
-42.00M
-68.00M
-299.00M
-297.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.27B
2.31B
2.91B
2.54B
Gain or loss from assets sale
65.00M
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps